BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 22312513)

  • 1. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience.
    Nace GW; Steel JL; Amesur N; Zajko A; Nastasi BE; Joyce J; Sheetz M; Gamblin TC
    Int J Surg Oncol; 2011; 2011():571261. PubMed ID: 22312513
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival Advantage of Yttrium-90 Radioembolization to Systemic Therapy in Patients with Hepatic Metastases from Colorectal Cancer in the Salvage Setting: Results of a Matched Pair Study.
    Haber Z; Lee EW; Price M; Wainberg Z; Hecht JR; Sayre J; Padia SA
    Acad Radiol; 2021 Nov; 28 Suppl 1():S210-S217. PubMed ID: 34099386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 Radioembolization as Salvage Therapy for Liver Metastases From Colorectal Cancer.
    Kalva SP; Rana RS; Liu R; Rachamreddy N; Dave B; Sharma A; Ganguli S; Rabito C; Kwak E; Blaszkowsky LS
    Am J Clin Oncol; 2017 Jun; 40(3):288-293. PubMed ID: 25374143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.
    Kennedy AS; Ball D; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Rose SC; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA
    J Gastrointest Oncol; 2015 Apr; 6(2):134-42. PubMed ID: 25830033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updated survival outcomes and analysis of long-term survivors from the MORE study on safety and efficacy of radioembolization in patients with unresectable colorectal cancer liver metastases.
    Kennedy A; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kaiser A; Nutting CW; Rose SC; Wang EA; Savin MA
    J Gastrointest Oncol; 2017 Aug; 8(4):614-624. PubMed ID: 28890810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Robust evidence for long-term survival with
    Jakobs TF; Paprottka KJ; Raeßler F; Strobl F; Lehner S; Ilhan H; Trumm CG; Fendler WP; Sommer W; Paprottka PM
    Eur Radiol; 2017 Jan; 27(1):113-119. PubMed ID: 27059858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine tumor liver metastases treated with yttrium-90 radioembolization.
    Fan KY; Wild AT; Halappa VG; Kumar R; Ellsworth S; Ziegler M; Garg T; Rosati LM; Su Z; Hacker-Prietz A; Pawlik TM; Cosgrove DP; Hong KK; Kamel IR; Geschwind JF; Herman JM
    Contemp Clin Trials; 2016 Sep; 50():143-9. PubMed ID: 27520932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.
    Kennedy AS; Ball DS; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Nutting CW; Moeslein FM; Putnam SG; Rose SC; Savin MA; Schirm S; Sharma NK; Wang EA
    J Gastrointest Oncol; 2015 Dec; 6(6):594-604. PubMed ID: 26697190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resin-based Yttrium-90 microspheres for unresectable and failed first-line chemotherapy intrahepatic cholangiocarcinoma: preliminary results.
    Jia Z; Paz-Fumagalli R; Frey G; Sella DM; McKinney JM; Wang W
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):481-489. PubMed ID: 27826686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective transarterial radioembolisation of unresectable liver-dominant colorectal cancer refractory to chemotherapy.
    Golfieri R; Mosconi C; Giampalma E; Cappelli A; Galaverni MC; Pettinato C; Renzulli M; Monari F; Mazzarotto R; Pinto C; Angelelli B
    Radiol Med; 2015 Aug; 120(8):767-76. PubMed ID: 25678128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy.
    Hendlisz A; Van den Eynde M; Peeters M; Maleux G; Lambert B; Vannoote J; De Keukeleire K; Verslype C; Defreyne L; Van Cutsem E; Delatte P; Delaunoit T; Personeni N; Paesmans M; Van Laethem JL; Flamen P
    J Clin Oncol; 2010 Aug; 28(23):3687-94. PubMed ID: 20567019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases.
    Jakobs TF; Hoffmann RT; Dehm K; Trumm C; Stemmler HJ; Tatsch K; La Fougere C; Murthy R; Helmberger TK; Reiser MF
    J Vasc Interv Radiol; 2008 Aug; 19(8):1187-95. PubMed ID: 18656012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS Status as an Independent Prognostic Factor for Survival after Yttrium-90 Radioembolization Therapy for Unresectable Colorectal Cancer Liver Metastases.
    Lahti SJ; Xing M; Zhang D; Lee JJ; Magnetta MJ; Kim HS
    J Vasc Interv Radiol; 2015 Aug; 26(8):1102-11. PubMed ID: 26210240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 90Y Radioembolization of Colorectal Hepatic Metastases Using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study.
    Hickey R; Lewandowski RJ; Prudhomme T; Ehrenwald E; Baigorri B; Critchfield J; Kallini J; Gabr A; Gorodetski B; Geschwind JF; Abbott A; Shridhar R; White SB; Rilling WS; Boyer B; Kauffman S; Kwan S; Padia SA; Gates VL; Mulcahy M; Kircher S; Nimeiri H; Benson AB; Salem R
    J Nucl Med; 2016 May; 57(5):665-71. PubMed ID: 26635340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Administered activity and outcomes of glass versus resin (90)Y microsphere radioembolization in patients with colorectal liver metastases.
    Srinivas SM; Nasr EC; Kunam VK; Bullen JA; Purysko AS
    J Gastrointest Oncol; 2016 Aug; 7(4):530-9. PubMed ID: 27563442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
    Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
    Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases.
    Chua TC; Bester L; Saxena A; Morris DL
    J Cancer Res Clin Oncol; 2011 May; 137(5):865-73. PubMed ID: 20859640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioembolization with Yttrium-90 microspheres for patients with unresectable hepatocellular carcinoma.
    Bhangoo MS; Karnani DR; Hein PN; Giap H; Knowles H; Issa C; Steuterman S; Pockros P; Frenette C
    J Gastrointest Oncol; 2015 Oct; 6(5):469-78. PubMed ID: 26487939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.